Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
There are typically densely cellular nests at the dermal-epidermal junction
1 Key results: Semaglutide 2.4 mg: -15.8% body weight loss Liraglutide 3 mg: -6.4% body weight loss Treatment difference: -9.4 percentage points in favour of semaglutide The proportion achieving clinically meaningful weight loss: Important note about Ozempic doses The STEP 8 trial used semaglutide 2.4 mg, which is the Wegovy dose for weight management
doi:10.3109/00016349109007165
We have noticed a similar upward trend in utilization and spend for GLP-1s across our book of business, with plan drug spend for Wegovy alone increasing over 500% between 2022 and 2023
US$ 29.41
US$ 25.18
US$ 24.20
US$ 27.61
US$ 24.18
US$ 24.07
